|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 1146699-66-2 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
Fields of Application :
BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively.
| CAS Number: | 1146699-66-2 |
| Purity: | >98% |
| Molecular Weight: | 520.88 |
| Molecular Formula: | C20H17ClF4N4O4S |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | BMS708163,BMS 708163 |
| Chemical Name: | (2R)-2-(N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)-4-chlorophenylsulfonamido)-5,5,5-trifluoropentanamide |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
Description of Avagacestat (BMS-708163): BMS-708163 (avagacestat) is an oral GSI designed For selective inhibition of Aβ synthesis currently in development For the treatment of mild to moderate and predementia AD. In addition to the desired effect on Aβ synthesis, GSIs affect Notch processing, which is thought to mediate some toxic adverse effects reported with this drug class. Avagacestat produced up to 190-fold greater selectivity For Aβ synthesis than Notch processing in preclinical studies and may there Fore produce less toxic adverse events than other less selective compounds. Results from this single-ascending dose study suggest that avagacestat was tolerated at a single-dose range of 0.3 to 800 mg and suitable For further clinical development. (source: Clin Ther. 2012 Mar;34(3):654-67. Epub 2012 Feb 28.). For the detailed information about the solubility of BMS-708163 in water, the solubility of BMS-708163 in DMSO, the solubility of BMS-708163 in PBS buffer, the animal experiment（test） of BMS-708163,the in vivo,in vitro and clinical trial test of BMS-708163,the cell experiment（test） of BMS-708163,the IC50, EC50 and Affinity of BMS-708163.
References:
C(N)(=O)[C@@H](N(CC1=CC=C(C2N=CON=2)C=C1F)S(C1=CC=C(Cl)C=C1)(=O)=O)CCC(F)(F)F
